Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BlueRock Therapeutics logo — Striving to transform the treatment of disease by harnessing...

BlueRock Therapeutics

Striving to transform the treatment of disease by harnessing the power of cell therapy

Founded 2016 United States Cambridge, United States 478 employees Acquired Total: $1.23B Biopharma, Biotechnology +1

General Information

Company Name BlueRock Therapeutics
Founded Year 2016
Location United States Cambridge, United States
Employees 478
Industries Biopharma, Biotechnology, Health Care
Funding Stage Acquired
Business Model B2B, B2C, B2B2C
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with BlueRock Therapeutics. To contact BlueRock Therapeutics, visit bluerocktx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BlueRock Therapeutics compare?

A PDF of BlueRock Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BlueRock Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BlueRock Therapeutics

BlueRock Therapeutics is a cutting-edge, clinical-stage cell therapy company dedicated to reshaping the landscape of disease treatment. Emphasizing the transformative potential of cell therapy, it has constructed a promising pipeline targeting severe neurological and ophthalmic conditions. Key clinical programs are pioneering novel therapies for Parkinson’s disease and primary photoreceptor diseases.

Founded in 2016, BlueRock Therapeutics was initially a joint venture involving Versant Ventures and Leaps by Bayer, becoming a wholly owned subsidiary of Bayer AG by late 2019. The company embodies values of resilience, mission-driven integrity, and a commitment to community.

In the rapidly evolving Biopharma sector, BlueRock Therapeutics stands out with a $1.00B acquisition investment by Bayer in August 2019, signifying strong backing and belief in its potential. With headquarters in the United States, it is uniquely poised to deliver groundbreaking cellular therapies.

Business keywords: Cell Therapy, Clinical Stage Biotech, Neurological Diseases, Ophthalmic Diseases, Parkinson’s Disease, Photoreceptor Diseases, Induced Pluripotent Stem Cells (iPSC), Regenerative Medicine, Heart Muscle Regeneration, Myocardial Infarction Treatment, Chronic Heart Failure, Engineered Cell Therapy, Biopharmaceuticals, Stem Cell Therapeutics, Genome Medicine

Services & Products

Development of Cell Therapies
Clinical Trial Management
Research and Development

Target Customers

Patients with Degenerative Diseases Healthcare Providers Medical Researchers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $1.00B 1
Bayer
Bayer
01 Aug 2019
Series A $225.00M 2
Versant Ventures Bayer
Versant Ventures, Bayer
01 Dec 2016

BlueRock Therapeutics Alternatives & Competitors

View All Alternatives
BlueRock Therapeutics vs
Heartseed Inc.
Heartseed Inc. Japan

Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiomyocytes fo...

IPO
20 employees
Biotechnology, Care Economy
BlueRock Therapeutics vs
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. United States

Focused on creating and delivering engineered cells as medicines for patients

IPO
257 employees
Biotechnology, Health Care
Compare BlueRock Therapeutics vs Sana Biotechnology, Inc.
BlueRock Therapeutics vs
Minerva Biotechnologies
Minerva Biotechnologies United States

We see the future first

17 employees
Biotechnology, Health Care
Also compare with: BlueRock Therapeutics vs NOVADIP Biosciences S.A. NOVADIP Biosciences S.A. BlueRock Therapeutics vs Tenaya Therapeutics Tenaya Therapeutics BlueRock Therapeutics vs Kenai Therapeutics Kenai Therapeutics View all alternatives

FAQ About BlueRock Therapeutics

Striving to transform the treatment of disease by harnessing the power of cell therapy
BlueRock Therapeutics was founded in 2016.
BlueRock Therapeutics is headquartered in Cambridge, United States.
BlueRock Therapeutics operates in Biopharma, Biotechnology and Health Care. Its work centres on Cell Therapy, Clinical Stage Biotech, Neurological Diseases and Ophthalmic Diseases. Its customers include Patients with Degenerative Diseases, Healthcare Providers and Medical Researchers.
BlueRock Therapeutics has a B2B, B2C and B2B2C business model. Its revenue comes from Licensing and Product Sales.
BlueRock Therapeutics has approximately 478 employees.
BlueRock Therapeutics has completed 2 funding rounds, raising a total of $1.23B. The latest funding stage is Acquired.
BlueRock Therapeutics offers: Development of Cell Therapies, Clinical Trial Management, Research and Development.
Top alternatives and competitors to BlueRock Therapeutics include Heartseed Inc., Sana Biotechnology, Inc., Minerva Biotechnologies, NOVADIP Biosciences S.A., Tenaya Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BlueRock Therapeutics and Heartseed Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BlueRock Therapeutics, https://bouncewatch.com/company/bluerock-therapeutics, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout